Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

NAActive, not recruitingINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

July 13, 2021

Study Completion Date

December 31, 2025

Conditions
Germ Cell TumorSex Cord Stromal TumorMalignant Non-epithelial Ovarian Tumors
Interventions
OTHER

Self-questionnaires of living conditions and quality of life

Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)

DIAGNOSTIC_TEST

Cardiac, pulmonary, auditory and biological assessment

"Patients will perform :~* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~* Blood tests"

Trial Locations (19)

Unknown

HEGP, Paris

Centre Paul Papin, Angers

CHU Besançon Jean MINJOZ, Besançon

Institut Bergonié, Bordeaux

CH Fleyriat, Bourg-en-Bresse

Centre François Baclesse, Caen

Centre Jean Perrin, Clermont-Ferrand

Centre Léon Berard, Lyon

Institut Paoli Calmettes, Marseille

Centre Catherine de Sienne, Nantes

Institut de Cancérologie de l'Ouest, Nantes

GH Cochin Broca Hôtel-Dieu, Paris

Hôpital Diaconesses-Croix St Simon, Paris

Institut Curie,, Paris

Institut Gustave Roussy, Paris

CHU Poitiers, Poitiers

Institut Jean Godinot, Reims

Institut Rennais de Cancérologie, Rennes

CHRU Stasbourg Hôpital Civil, Strasbourg

All Listed Sponsors
collaborator

ARCAGY/ GINECO GROUP

OTHER

lead

Centre Francois Baclesse

OTHER

NCT03418844 - Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy | Biotech Hunter | Biotech Hunter